- Home
- ABBV vs C Comparison
ABBV vs C Comparison
Compare ABBV & C Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABBV | C |
|---|---|---|
| Founded | 2012 | 1812 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.5B | 225.2B |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ABBV | C |
|---|---|---|
| Price | $285.55 | $121.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 23 |
| Target Price | ★ $282.61 | $150.71 |
| AVG Volume (30 Days) | 3.2M | ★ 6.9M |
| Earning Date | 10-30-2026 | 10-13-2026 |
| Dividend Yield | ★ 2.43% | 2.19% |
| EPS Growth | N/A | ★ 17.68 |
| EPS | 2.42 | ★ 6.99 |
| Revenue | $61,160,000,000.00 | ★ $85,225,000,000.00 |
| Revenue This Year | $10.57 | $12.57 |
| Revenue Next Year | $8.79 | $4.34 |
| P/E Ratio | $117.54 | ★ $17.57 |
| Revenue Growth | ★ 8.57 | 5.04 |
| 52 Week Low | $190.75 | $95.83 |
| 52 Week High | $291.40 | $147.96 |
Technical Indicators
Market Signals| Indicator | ABBV | C |
|---|---|---|
| Relative Strength Index (RSI) | 65.69 | 35.34 |
| Support Level | $204.45 | $119.76 |
| Resistance Level | $291.40 | $125.16 |
| Average True Range (ATR) | 6.96 | 3.16 |
| MACD | 0.73 | -0.34 |
| Stochastic Oscillator | 83.53 | 8.28 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About C Citigroup Inc.
Citigroup is a global financial powerhouse that orchestrates the movement of over $6 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm services 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, it has taken steps to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.